Mental Heal

Company Overview

Snapshot

Founded in October 2012 by Santiago Ini, Mental Heal operates with 1–10 employees. The company is developing a novel oral antipsychotic drug, PGW-5, for the treatment of schizophrenia and bipolar disorder. Mental Heal has secured funding across one round from Office of the Chief Scientist and Abital.

Business overview

Mental Heal, operating in the Health Tech & Life Sciences sector, is focused on developing PGW-5, a novel oral antipsychotic drug. This neuroleptic, multi-target agent is designed to treat schizophrenia symptoms, cognitive deficits, and mood disorders. The company's research suggests PGW-5 may influence the brain's glutamate NMDA system, neurotrophic factors, and food intake regulating peptides, with early animal model studies indicating anxiolytic and antidepressant activity, alongside improved social performance in PCP-treated mice. Mental Heal primarily serves the pharmaceutical market with its B2B business model.

Company Intelligence Q&A

What is Mental Heal's primary therapeutic focus?

Mental Heal is developing PGW-5, a novel oral antipsychotic drug for the treatment of schizophrenia and bipolar disorder, targeting symptoms, cognitive deficits, and mood disorders.

Who founded Mental Heal?

Mental Heal was founded by Santiago Ini, who also serves as the CEO.

What is the current development stage of Mental Heal's product?

Mental Heal's primary product, PGW-5, is currently in the R&D stage, as of its last update in October 2016.

What is the mechanism of action for Mental Heal's drug candidate PGW-5?

The possible mechanisms underlying PGW-5's effects may involve the brain glutamate NMDA system, neurotrophic factors, and food intake regulating peptides.

Which investors have participated in Mental Heal's funding rounds?

Mental Heal has received funding from investors including Office of the Chief Scientist and Abital.